Targets › NAPRT1
1 program from 1 company in 1 trial: 1 Phase 1; Other.
Catalyzes the first step in the biosynthesis of NAD from nicotinic acid, the ATP-dependent synthesis of beta-nicotinate D-ribonucleotide from nicotinate and 5-phospho-D-ribose 1-phosphate. Helps prevent cellular oxidative stress via its role in NAD biosynthesis. (UniProt, Q6XQN6)
Open in Phaseline: the race on NAPRT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ChromaDex | Niagen® Plus Nicotinamide riboside (NR) precursor; boosts NAD+ biosynthesis via salvage pathway | NAPRT1 | Phase 1 | Healthy Volunteer | – |
Healthy Volunteer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.